Language Selection

Get healthy now with MedBeds!
Click here to book your session

Protect your whole family with Orgo-Life® Quantum MedBed Energy Technology® devices.

Advertising by Adpathway

         

 Advertising by Adpathway

Computational Modeling Identifies Quinolinol Analogues Outperforming Tamoxifen Against Breast Cancer Target

1 day ago 22

PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY

Orgo-Life the new way to the future

  Advertising by Adpathway

Computational drug design investigations have identified quinolinol-based chemical analogues that demonstrate substantially stronger binding affinities and greater structural stability against human estrogen receptor alpha than the conventional breast cancer drug 4-hydroxytamoxifen. Estrogen receptor alpha serves as a primary transcription factor and validated clinical target in hormone-dependent MCF-7 breast cancer, a major driver of cancer-related mortality worldwide. Luminal subtypes A and B, which account for roughly 70 to 75 percent of all clinical breast cancer diagnoses, rely on estrogen receptor alpha to activate the genomic transcription of genes responsible for cellular proliferation and angiogenesis. While selective estrogen receptor modulators such as tamoxifen and its liver metabolite 4-hydroxytamoxifen represent standard endocrine interventions, extended clinical usage frequently leads to acquired drug resistance through ESR1 gene mutations or problematic adverse effects, including endometrial hyperplasia. Consequently, developing structurally diverse antagonists featuring nitrogen-containing heterocyclic scaffolds represents an urgent therapeutic objective.

To discover therapeutic candidates capable of addressing these clinical challenges, researchers applied an integrated computer-aided drug design pipeline to examine a panel of quinolinol analogues. In medicinal chemistry, the quinolinol ring system represents an established privileged scaffold, possessing a planar bicyclic heteroaromatic geometry that fits precisely into hydrophobic protein pockets. This structure engages in essential pi-pi stacking interactions with aromatic residues such as phenylalanine, tyrosine, and tryptophan, while presenting nitrogen and hydroxyl groups capable of forming directional hydrogen bonds. Modifications at positions C-3, C-6, and C-8 hold considerable promise for modulating biological activity against MCF-7 cells. By utilizing computational modeling tools within the Maestro 12.8 software platform, the investigation established an accelerated workflow to assess biological and pharmacokinetic properties. The multi-tiered analysis combined Gaussian field-based three-dimensional quantitative structure-activity relationship modeling, pharmacophore hypothesis generation, predictive ADMET screening using the ADMETlab 3.0 server, extra-precision molecular docking, 100-nanosecond GROMACS molecular dynamics simulations, and density functional theory calculations.

The research team initiated the ligand-based branch of their pipeline by gathering 32 candidate molecules with documented antiproliferative activity against the hormone-dependent MCF-7 breast cancer cell line from the PubChem database. The experimental biological activities of these compounds had been originally determined through standard MTT colorimetric cell viability assays, with recorded half-maximal inhibitory concentration values spanning a broad range from 2.1 to 45.01 micromolar. These laboratory measurements were converted into negative base-ten logarithmic pIC50 values to facilitate quantitative regression modeling. Each chemical structure was drawn using ChemDraw Professional 16.0 and subsequently prepared through the LigPrep module and Epik tool under the OPLS4 force field, generating low-energy conformers that underwent desalting and ionization adjustment to physiological pH. Following systematic structural curation, 10 compounds were eliminated because of structural features that prevented reliable molecular alignment, leaving a refined dataset containing 22 quinolinol derivatives that formed the foundation for all subsequent modeling steps.

To establish correlations between molecular features and experimental potency, the authors developed a field-based three-dimensional quantitative structure-activity relationship model. The curated dataset of 22 quinolinol compounds was randomly partitioned into a training set comprising 70 percent of the molecules and a testing set containing the remaining 30 percent to minimize selection bias. By applying partial least squares regression to relate measured pIC50 values against five Gaussian field descriptors—steric, electrostatic, hydrophobic, hydrogen bond acceptor, and hydrogen bond donor fields—the researchers optimized predictive performance. The optimal model evaluated at partial least squares factor 3 exhibited outstanding statistical quality, including a coefficient of determination R2 of 0.9516, a cross-validated predictive ability Q2 of 0.5989, a root mean square error of 0.82, a standard deviation of 0.2699, and a cross-validation coefficient R2CV of 0.8107. The regression generated an F-value of 102.9 and a P-value of 6.78 × 10^-18, while response permutation analysis yielded a low scrambling R2 score of 0.1933, confirming that the model did not arise from random chance correlations.

External validation of the quantitative structure-activity relationship model yielded a Pearson correlation coefficient of 0.845 between observed and predicted activities across the external test set. Spatial contour maps derived from the Gaussian fields revealed specific architectural modifications required to maximize inhibitory activity against MCF-7 cells. Steric fields contributed 36.36 percent of the total contour variance, while hydrophobic and hydrogen bond acceptor fields accounted for 21.7 percent and 21.13 percent, respectively. Hydrogen bond donor fields contributed 10.64 percent and electrostatic fields represented 9.85 percent. Green steric contour regions indicated that bulky substituents at the C-3, C-6, and C-8 positions of the quinolinol scaffold significantly enhanced antiproliferative potency. Red electrostatic contours along the outer margins of C-3, C-6, and C-8 favored electronegative, electron-withdrawing groups, whereas blue regions near C-4 through C-7 favored electropositive, electron-donating groups. Favorable hydrophobic zones clustered near C-3, C-6, and C-8, whereas hydrophobic substitutions near position C-7 were predicted to decrease biological potency.

Complementing the field-based contour modeling, the authors performed pharmacophore hypothesis generation using the Phase module within Maestro 12.8 to identify the three-dimensional arrangement of chemical features driving receptor engagement. The analysis screened six fundamental pharmacophoric descriptors across the active compound library: hydrogen bond donors, hydrogen bond acceptors, aromatic rings, hydrophobic groups, positive charge centers, and negative charge centers. Compounds possessing pIC50 values of 6.5 or greater were designated active, while those exhibiting values of 4.5 or lower were classified as inactive. The resulting optimal hypothesis revealed that an aromatic ring feature, a hydrophobic region, and a hydrogen bond acceptor constitute the indispensable chemical triad necessary for robust inhibitory activity against MCF-7 cells.

To ensure that candidates identified through ligand-based modeling possessed suitable drug-like behavior, the investigators performed comprehensive ADMET evaluations using the ADMETlab 3.0 computational server. The screening characterized physicochemical properties, pharmacokinetic profiles, and predicted toxicity liabilities across the entire 22-compound series, assigning each analogue an integrated total score. Compounds 1, 7, 25, and 13 achieved the highest total ADMET scores at 6.348, 6.213, 5.768, and 5.706, respectively, reflecting an optimal combination of aqueous solubility, lipophilicity, oral bioavailability, and lower risk of organ toxicity. Compound 1, corresponding to the parent scaffold 8-hydroxyquinoline, exhibited a favorable lipophilicity logP of 2.15, an aqueous solubility logS of -1.56, and a low predicted hERG potassium channel inhibition score of 0.080. Compound 7, characterized by a methyl substitution, displayed a balanced medicinal chemistry profile with a quantitative estimate of drug-likeness of 0.639, a synthetic accessibility score of 1.821, an Fsp3 score of 0.10, and high predicted in vivo oral bioavailability of 0.809.

All 22 evaluated quinolinol derivatives fulfilled Lipinski’s Rule of Five and the GlaxoSmithKline pharmacokinetic filter, with compounds 1, 7, 25, and 13 additionally meeting the Golden Triangle criterion for balanced molecular weight and lipophilicity. However, detailed toxicity profiling uncovered notable liability patterns across specific functional groups. While compounds 13, 1, 25, and 7 displayed low hERG channel liability scores of 0.066, 0.080, 0.086, and 0.117 along with low-to-moderate drug-induced liver injury risks, analogues bearing bulky tertiary amino-alkyl substituents—specifically compounds 9, 10, 18, and 24—showed elevated hERG inhibition liabilities of 0.608 and 0.546. Halogenated derivatives 2, 3, 6, and 22 exhibited intense plasma protein binding alongside compromised oral bioavailability and elevated liver toxicity predictions linked to higher lipophilicity. Furthermore, N-hydroxyl-substituted analogues 4 and 27 generated severe liver injury scores exceeding 0.82 due to their tendency to generate reactive oxygen species, confirming that methyl substitution in compound 7 provided the most favorable pharmacokinetic safety balance.

Structure-based molecular docking was subsequently conducted to characterize binding affinities and contact networks within the ligand-binding domain of human estrogen receptor alpha, utilizing the 1.9-angstrom crystallographic structure under Protein Data Bank identifier 3ERT. The docking methodology was validated by re-docking the co-crystallized reference antagonist 4-hydroxytamoxifen, which reproduced the experimental binding pose with a root-mean-square deviation below 2.0 angstroms. When docked using Glide extra-precision protocols, the prioritized quinolinol derivatives occupied the same orthosteric pocket as 4-hydroxytamoxifen and established superior calculated binding affinities. Methyl-substituted compound 7 achieved the highest docking score of -11.98 kilocalories per mole, outperforming compound 1 at -11.48, compound 25 at -11.04, and compound 13 at -9.46 kilocalories per mole, all exceeding 4-hydroxytamoxifen at -8.26 kilocalories per mole. Contact analyses revealed that compound 7 engaged key stabilizing residues, including Leu346, Leu349, Ala350, Glu353, Arg394, Gly390, Leu525, Met357, and Phe404, while forming strong pi-pi stacking against Arg394 and core hydrogen bonding with Pro325.

To evaluate dynamic stability under physiological conditions, the researchers conducted 100-nanosecond molecular dynamics simulations in GROMACS 2021.6 using the CHARMM36 force field and explicit TIP3P water solvation. Compound 7 stabilized rapidly within 15 nanoseconds, maintaining a steady root-mean-square deviation between 0.24 and 0.28 nanometers, while 4-hydroxytamoxifen showed substantial fluctuations. Radius of gyration values remained consistent at 2.30 to 2.34 nanometers, but compound 7 maintained tighter compactness, active-site residue fluctuations below 0.20 nanometers, and sustained two to five hydrogen bonds with an optimal distance peak at 0.29 to 0.31 nanometers. Density functional theory calculations at the B3LYP/6-311G+(d,p) level confirmed compound 7 possessed higher kinetic stability, with a wider frontier orbital energy gap of 4.2119 electronvolts compared to 2.8552 electronvolts for 4-hydroxytamoxifen. While these findings establish compound 7 as a promising computationally designed lead, the authors cautioned that the model was developed on 22 compounds and requires empirical validation through in vitro and in vivo studies to confirm biological efficacy and receptor selectivity.

Subject of Research: In silico discovery and molecular characterization of quinolinol-based estrogen receptor alpha antagonists for MCF-7 breast cancer

Article Title: Computational identification of quinolinol based estrogen receptor alpha antagonists as promising therapeutics for MCF 7 breast cancer

Article References: Garhewal, M., Pujari, D., Bhattacharya, A., Tiwari, A., Mishra, A., Agrawal, A., Verma, S., Mishra, A., & Vaishnav, Y. (2026). Computational identification of quinolinol based estrogen receptor alpha antagonists as promising therapeutics for MCF 7 breast cancer. Discover Chemistry, 3(1), Article 633. https://doi.org/10.1007/s44371-026-01046-0

Image Credits: AI Generated

DOI: 10.1007/s44371-026-01046-0

Keywords: quinolinol derivatives, estrogen receptor alpha, MCF-7 breast cancer, computer-aided drug design, 3D-QSAR modeling, molecular docking, molecular dynamics simulation, density functional theory, pharmacophore modeling, ADMET profiling, 4-hydroxytamoxifen, ligand 7, GLIDE docking, CHARMM36 forcefield, binding affinity, GROMACS simulation

Read Entire Article

         

        

Start the new Vibrations with a Medbed Franchise today!  

Protect your whole family with Quantum Orgo-Life® devices

  Advertising by Adpathway